Date: October 26, 2022

From: Felecia Peterson
IRB Analyst, Human Research Protection Office

Subject: CDC Institutional Review Board (IRB) Approval of Amendment #6 of the Expanded Access Investigational New Drug (IND) protocol "Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children", Version 6.2 (IND 116039/CDC #6402)

To: Brett Petersen, MD, MPH
CDC National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)

The CDC IRB has reviewed and approved the proposed changes to the Expanded Access IND protocol titled “Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children” during the period for which IRB approval has been given in accordance with 21 CFR 56.108(a)(4). The approved changes include:

- Added tecovirimat treatment availability through a randomized controlled clinical trial under Section 2.1 Tecovirimat Eligibility of the protocol.
- Added clarifying language regarding the labeled contraindication of IV tecovirimat use in patients with severe renal impairment and certain exceptions allowed based on individual risk-benefit assessment and clinical determination by the treating providers in consultation with CDC.
- Updated oral tecovirimat dose for infants weighing less than 3 kg and dose preparation instructions for children who weigh less than 3 kg or weigh between 3 kg to less than 6 kg per FDA recommendations. Corresponding Attachment 3: Opening Capsules and Mixing with Food/Liquid Instructions was also updated accordingly.
- Added clarifying language regarding clinical considerations for treatment duration beyond the standard 14-day course at a short increment of extension with monitoring for clinical improvement, virologic response or lack of response to reassess continuation or discontinuation for treatment.
- Added information on the implementation of online registry required for new providers and transition to electronic Patient Intake and Clinical Outcome forms.
- Added selected adverse events of interest for monitoring and reporting to CDC.

Reminder: CDC IRB approval of this Expanded Access IND protocol will still expire on July 23, 2023.

CDC investigators must report any unanticipated problems, or instances of serious or continuing noncompliance as described at 21 CFR 56.108 to the CDC IRB in accordance with CDC standard operating procedures. Any proposed changes to this Expanded Access IND protocol, informed consent, other approved materials, or new materials, must be submitted to the CDC IRB for review and approval prior to implementation except where necessary to eliminate apparent immediate hazards to the human subjects.

If you have any questions, please contact the NCEZID Human Subjects Contact or the CDC Human Research Protection Office at (404) 639-7570 or by e-mail at huma@cdc.gov.

cc: NCEZID Human Studies
Nicole Cohen, MD (CDC IRB Chair)